creat bluematrix
messag report result ahead street though note
consensu accur total revenue complement franchis perform
bit mix soliri sale flat despit one extra infus day
substanti contribut neurolog indic sale eu though
benefit robust row growth could ultomiri convers track
ahead expect germani japan uptak seem alreadi slow
 metobol came bit ahead street estimate bump revenue non-
gaap ep guidanc respect bracket
estim
call detail et dial
franchis consensu ultomiri
convers begin slow soliri antibodi perform weak
despit strong growth mg indic
soliri sale littl weak come q/q y/i
consensu consid somewhat
underwhelm volum growth y/i patient addit neurolog
indic strong compani ad patient across mg
nmosd vs patient given substanti boost mg patient
modest anticip contribut nmosd coupl one extra infus day
worth soliri perform bit puzzl us soliri sale
particularli strong row sale vs think
could relat tender acknowledg portion pnh patient
switch less expens ultomiri would expect
compens mg patient growth
ultomiri manag aggress attempt convert pnh/ahu patient
came third full quarter market sale slightli
ahead consensu pnh patient
convert soliri ultomiri slower growth
expect vs growth past two
quarter respect manag note launch move beyond treatment
center excel move broader treatment base believ
could lead somewhat slower growth account larger physician educ
burden place sale forc also note convers year
drug avail sinc decemb still incred rapid pace
convers ultomiri uptak occur markedli faster manag goal
convers year
metabol decent quarter driven primarili strensiq strensiq ert
decent quarter though kanuma lal-d ert disappoint strensiq came
y/i revenue growth y/i volum growth consensu
meanwhil kanuma came y/i growth y/i volum
growth consensu metabol portfolio whole came
consensu increas metabol guidanc
updat view fcrn antibodi one promis
asset current pipelin compani plan initi phase ii trial
compound warm autoimmun heolyt anemia waiha earli
subq phase ii studi gmg last quarter manag note expect
begin phase ii mg trial iv formul
page analyst certif import disclosur
updat formul somewhat unclear whether program
discontinu whether phase iv phase ii subq program could on-going
simultan
financi total revenue came vs consensu estim
respect non-gaap ep come q/q y/
ahead consensu estim
guidanc bump base today result manag increas revenu
guidanc non-gaap ep bracket
consensu top line believ readili achiev
page analyst certif import disclosur
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst research associ receiv compens base upon variou factor includ qualiti research investor client
feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic alexion
pharmaceut inc next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori inc
creat bluematrix
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within
sell describ stock expect provid total neg return price appreci plu yield within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/or
cs coverag suspend guggenheim secur llc suspend coverag compani
nc cover guggenheim secur llc cover compani
monitor describ stock whose compani fundament financi monitor financi project opinion
invest merit compani provid
review ur follow releas signific news compani rate temporarili place review suffici
inform obtain assess analyst
guggenheim secur llc methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ restrict analys
market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash flow ev/ebitda price-to-earnings pe/growth
price-to-cf p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
price target assign buy- sell-rat stock price target neutral-r stock provid discret analyst
page analyst certif import disclosur
equiti valuat risk valuat methodolog risk associ cover compani price target cover compani pleas
see recent company-specif research report http //guggenheimlibrari bluematrix com/client/librari jsp contact primari analyst
guggenheim secur llc repres email
